Biomm (BIOM3) Q2 2025 earnings summary

Executive summary

• 2Q25 net revenue fell 15% YoY to R$27.2m, mainly due to Herzuma discontinuation; lower Glargilin sales volume drove the sequential decline.

• 2Q25 net loss narrowed to R$13.7m from R$18.3m YoY; H1 net loss narrowed to R$25.5m from R$35.4m.

• Growth priorities include biotech portfolio expansion, higher local Glargilin production, strategic partnerships and public-sector supply programs.

Financial highlights

• 2Q25 gross profit rose 8% YoY to R$8.7m; H1 gross profit fell 3% YoY to R$16.1m, with higher costs following production start at Nova Lima.

• Operating expenses declined 25% YoY to R$21.6m in 2Q25, reflecting lower marketing and administrative expenses.

• H1 operating cash flow was negative R$58.9m; June cash and equivalents were R$16.5m, down from R$77.6m at year-end 2024.

• 2Q25 cash and financial investments totaled R$80.3m.

Segment performance

• BIOMM glargine sales declined 24% YoY in 2Q25 versus a 13% market decline; Jun. 2025 LTM sales rose 38% versus 13% market growth.

• BIOMM glargine share was 24% in 2Q25 versus 27% in 2Q24; Jun. 2025 LTM share reached 34% versus 24% a year earlier.

• Glargilin led the public insulin glargine market with 37.9% share; Wosulin reached a record 36.4% share of public human insulin.

• Ghemaxan private-channel sales grew 15.2% YoY; Jun. 2025 LTM private-market enoxaparin sales rose 29% while the market declined 8%.

• Public-market Wosulin deliveries rose 6,365% YoY, while private-market human insulin sales fell 48.7%; H1 sales volume mix was 81% Glargilin, 16% Wosulin and 3% Ghemaxan.